Management of Aspirin in Patients with Intracranial Bleeding and Cardiac Stent

Risk Assessment and Management

• In patients with intracranial bleeding and a cardiac stent, aspirin should be temporarily discontinued if the hemorrhagic risk is major, but should be resumed as soon as possible after bleeding is controlled, according to the British Journal of Anaesthesia 1, 2
• The decision to stop aspirin therapy requires careful consideration of two competing risks: hemorrhagic risk and thrombotic risk, with the British Journal of Anaesthesia citing the importance of weighing these risks 1
• The risk of hemorrhage is influenced by factors such as the severity of intracranial hemorrhage, location of bleeding, and active vs. stabilized bleeding, as noted by the British Journal of Anaesthesia 1, 2, 3
• The risk of thrombosis is influenced by factors such as the type of stent, time since stent placement, and use of dual antiplatelet therapy, with the Journal of Neurointerventional Surgery highlighting the importance of considering these factors 3, 4
• Drug-eluting stents have a higher thrombotic risk than bare-metal stents and require longer duration of dual antiplatelet therapy, according to the Journal of Neurointerventional Surgery 4
• The American College of Cardiology recommends maintaining aspirin therapy for at least 1 year after placement of a drug-eluting stent, as cited in the Journal of Neurointerventional Surgery 4, 3
• For patients with intermediate bleeding risk and high stent thrombosis risk, aspirin should be maintained if possible, with the British Journal of Anaesthesia recommending this approach 1, 2
• If aspirin must be discontinued, it should be resumed as soon as possible, with the British Journal of Anaesthesia emphasizing the importance of prompt resumption 1, 2
• The risk of major hemorrhage is significantly increased with dual antiplatelet therapy compared to single antiplatelet therapy, as noted by the Journal of Neurointerventional Surgery 4, 3

Special Considerations

• For patients with drug-eluting stents, aspirin therapy should be maintained for at least 1 year after placement, with the Journal of Neurointerventional Surgery recommending this approach 4, 3
• If dual antiplatelet therapy is used, consider stopping only clopidogrel while maintaining aspirin if possible, with the British Journal of Anaesthesia citing this as a potential strategy 1, 2
• When resuming clopidogrel, consider a loading dose of at least 300 mg, as recommended by the British Journal of Anaesthesia 1

Follow-up Recommendations

• Close monitoring for signs of stent thrombosis or recurrent bleeding is recommended, with the British Journal of Anaesthesia emphasizing the importance of close monitoring 1
• Aspirin should be resumed at the earliest safe opportunity, with the British Journal of Anaesthesia recommending prompt resumption 1, 2
• Consider a lower maintenance dose of aspirin (75-100 mg) when resuming therapy, with the Journal of Neurointerventional Surgery and Circulation citing this as a potential approach 4, 6